Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update

Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a significant growth in short interest in the month of February. As of February 28th, there was short interest totalling 1,400,000 shares, a growth of 76.1% from the February 13th total of 795,200 shares. Approximately 1.6% of the shares of the stock are sold short. Based on an average trading volume of 1,090,000 shares, the short-interest ratio is currently 1.3 days.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on UNCY shares. Benchmark reaffirmed a "speculative buy" rating and set a $3.00 price objective on shares of Unicycive Therapeutics in a report on Friday, November 22nd. HC Wainwright reaffirmed a "buy" rating and set a $4.00 price objective on shares of Unicycive Therapeutics in a report on Wednesday, January 29th.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in UNCY. Great Point Partners LLC purchased a new position in shares of Unicycive Therapeutics in the third quarter valued at $3,491,000. Nantahala Capital Management LLC increased its position in shares of Unicycive Therapeutics by 268.5% in the fourth quarter. Nantahala Capital Management LLC now owns 10,391,994 shares of the company's stock valued at $8,253,000 after buying an additional 7,571,636 shares in the last quarter. Vivo Capital LLC increased its position in shares of Unicycive Therapeutics by 123.0% in the fourth quarter. Vivo Capital LLC now owns 9,970,152 shares of the company's stock valued at $7,918,000 after buying an additional 5,500,000 shares in the last quarter. Walleye Capital LLC purchased a new position in shares of Unicycive Therapeutics in the third quarter valued at $2,040,000. Finally, Acuta Capital Partners LLC purchased a new position in shares of Unicycive Therapeutics in the third quarter valued at $807,000. Hedge funds and other institutional investors own 40.42% of the company's stock.

Remove Ads

Unicycive Therapeutics Stock Up 2.4 %

UNCY stock traded up $0.01 on Tuesday, reaching $0.59. 473,687 shares of the company's stock were exchanged, compared to its average volume of 949,105. The firm has a market cap of $61.74 million, a PE ratio of -0.61 and a beta of 2.26. Unicycive Therapeutics has a twelve month low of $0.20 and a twelve month high of $1.60. The stock has a fifty day moving average of $0.60 and a 200-day moving average of $0.55.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.